Sign in
Active, not recruitingPhase 1/2

A Clinical Study of Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Premature Ovarian Insufficiency

Key facts

Who runs it
International Peace Maternity and Child Health Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 1/2
People taking part
60 people, planned
Started
20 Mar 2026
Expected to end
31 Dec 2028
Type of study
Interventional, 2 groups
Treatments tested
  • YT023
  • Control Arm (Conventional Therapy)
Record updated
3 April 2026

Who can take part

Age
20 years to 39 years
Sex
Women only
Healthy volunteers
Cannot take part
Show the full registry criteria (2)Hide the full registry criteria

Who can take part

  • Able to understand and voluntarily sign the informed consent form (ICF) prior to the initiation of any study-related assessments or procedures; Aged 20 to 39 years (inclusive) at the time of signing the ICF; Meets the diagnostic criteria for premature ovarian insufficiency (POI) ; Has a normal karyotype and no known history of FMR1 premutation (Fragile X syndrome); Has at least one ovary intact

Who cannot take part

  • History of primary malignancy; Subjects who are hepatitis B surface antigen (HBsAg)-positive at screening; subjects who are HBsAg-negative but hepatitis B core antibody (HBcAb)-positive with detectable peripheral blood hepatitis B virus (HBV) DNA above the lower limit of detection; subjects who are hepatitis C virus (HCV) antibody-positive with detectable HCV RNA; or subjects who are human immunodeficiency virus (HIV) antibody-positive; Known hypersensitivity to any component of the study treatments; Severe neurocognitive impairment as judged by the investigator; Any comorbidities or other conditions that, in the investigator's opinion, may affect compliance with the protocol or render the subject unsuitable for participation in the study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Clinical Study of Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Premature Ovarian Insufficiency

The 2 groups in the trial

  • YT023Treatment being tested

    YT023 treatment group will receive assisted reproductive therapy in accordance with the standard of care at the study site after YT023 treatment

  • Control armOther group

    The control group will receive assisted reproductive therapy in accordance with the standard of care at the study site

    Treatment: Control Arm (Conventional Therapy)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
3 April 2026